The Netherlands Cancer Institute-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:The Netherlands Cancer Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013361
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
The Netherlands Cancer Institute (NCI) is a research institute that offers cancer research and treatment services. The institute conducts research in the areas of cell biology, diagnostic oncology, medical oncology, molecular carcinogenesis, biochemistry, biological stress response, gene regulation, immunology, psychosocial research, and epidemiology, among others. It offers scientific and clinical development and training services. NCI provides education to postdoctoral fellows, PhD students and technicians. The institute offers courses in the fields of biology, medicine, chemistry and basic medical statistics course. It operates facilities including bioanalytical laboratory of the pharmacy, biostatistics center, carcinogen laboratory, digital microscopy facility and flow cytometry facility, protein facility, and others. NCI is headquartered in Amsterdam, the Netherlands.

The Netherlands Cancer Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Netherlands Cancer Institute, Medical Devices Deals, 2011 to YTD 2017 9
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 11
Neon Therapeutics Enters into Research Agreement with Netherlands Cancer Institute 12
Elekta Enters Into Agreement With Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital For Cancer Solutions 13
Agendia Enters Into Collaboration With AstraZeneca And The Netherlands Cancer Institute 14
Licensing Agreements 15
Neon Therapeutics Enters into Licensing Agreement with Netherlands Cancer Institute 15
Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 16
The Netherlands Cancer Institute – Key Competitors 17
The Netherlands Cancer Institute – Key Employees 18
The Netherlands Cancer Institute – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Government and Public Interest 20
Aug 22, 2017: Studies highlight ‘potential new targets for immunotherapy’ 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Key Facts 2
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Netherlands Cancer Institute, Deals By Therapy Area, 2011 to YTD 2017 8
The Netherlands Cancer Institute, Medical Devices Deals, 2011 to YTD 2017 9
The Netherlands Cancer Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 11
Neon Therapeutics Enters into Research Agreement with Netherlands Cancer Institute 12
Elekta Enters Into Agreement With Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital For Cancer Solutions 13
Agendia Enters Into Collaboration With AstraZeneca And The Netherlands Cancer Institute 14
Neon Therapeutics Enters into Licensing Agreement with Netherlands Cancer Institute 15
Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 16
The Netherlands Cancer Institute, Key Competitors 17
The Netherlands Cancer Institute, Key Employees 18
The Netherlands Cancer Institute, Subsidiaries 19

★海外企業調査レポート[The Netherlands Cancer Institute-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nuri Telecom Co., Ltd. (040160):企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Phillips 66 Co (PSX)-石油・ガス分野:企業M&A・提携分析
    Summary Phillips 66 Company (Phillips 66) is a diversified energy manufacturing and logistics company. It gathers, processes, transports and markets natural gas and petroleum products such as gasoline, diesel, aviation fuel and lubricants, and transports, fractionates and markets natural gas liquids …
  • DH Private Equity Partners:企業の戦略・SWOT・財務分析
    DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report Summary DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • KT Corporation:企業の戦略・SWOT・財務情報
    KT Corporation - Strategy, SWOT and Corporate Finance Report Summary KT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ContraVir Pharmaceuticals Inc (CTRV):製薬・医療:M&Aディール及び事業提携情報
    Summary ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formu …
  • Hanesbrands Inc (HBI):企業の財務・戦略的SWOT分析
    Hanesbrands Inc (HBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Enercon Services Inc:企業の戦略的SWOT分析
    Enercon Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Emergent BioSolutions Inc (EBS):企業の財務・戦略的SWOT分析
    Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Argan Inc (AGX):企業の財務・戦略的SWOT分析
    Argan Inc (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Mainstream Renewable Power Ltd-エネルギー分野:企業M&A・提携分析
    Summary Mainstream Renewable Power Ltd (Mainstream) develops, finances, constructs, and operates large-scale renewable energy plants. It develops and builds onshore and offshore wind and solar power plants. The company sells the plants to its natural owners including utilities, energy intensive corp …
  • Taiheiyo Cement Corporation:企業の戦略・SWOT・財務分析
    Taiheiyo Cement Corporation - Strategy, SWOT and Corporate Finance Report Summary Taiheiyo Cement Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Rosenergoatom Concern:企業の戦略的SWOT分析
    Rosenergoatom Concern - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • The Interpublic Group of Companies, Inc. (IPG):企業の財務・戦略的SWOT分析
    The Interpublic Group of Companies, Inc. (IPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Amcor Limited:企業の戦略・SWOT・財務分析
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • iX Biopharma Ltd (42C):企業の財務・戦略的SWOT分析
    Summary iX Biopharma Ltd (iX Biopharma) is a pharmaceutical company that provides that offers drug delivery and formulation. The company's pipeline product portfolio includes development of drugs for various indications such as opioid-sparing for acute, severe and chronic pain; male erectile dysfunc …
  • S P Setia Berhad (SPSETIA):企業の財務・戦略的SWOT分析
    S P Setia Berhad (SPSETIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Radiation Monitoring Devices Inc:製品パイプライン分析
    Summary Radiation Monitoring Devices Inc (RMD), a subsidiary of Dynasil Corporation of America is a research and development company that provides solutions for security, medical and industrial applications. The company’s products include scintillators, APDs, cesium iodide, solid state photomultipli …
  • Ego Pharmaceuticals Pty Ltd:企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • China Ming Yang Wind Power Group Ltd-エネルギー分野:企業M&A・提携分析
    Summary China Ming Yang Wind Power Group Limited (Ming Yang) is a wind equipment company that designs, manufactures, sells and services wind turbines. It also provides services such as technical training, transportation of wind turbines, installation of wind turbines, debugging service of wind gener …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆